Acumen Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $127.88M
- P/E (TTM)
- –
- Dividend yield
- –
About Acumen Pharmaceuticals
Biological Products, (No Diagnostic Substances), SIC 2836
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted disease-modifying therapies for Alzheimer’s disease. Its lead product candidate, sabirnetug (ACU193), is a recombinant humanized monoclonal antibody designed to selectively bind and neutralize soluble amyloid-beta oligomers, which are neurotoxic assemblies implicated in synaptic dysfunction and neurodegeneration. In addition to sabirnetug, the company is advancing blood-brain barrier-penetrating enhanced brain delivery therapies for Alzheimer’s pathology. As a clinical-stage enterprise, its candidates target individuals diagnosed with early Alzheimer’s disease, encompassing those with mild cognitive impairment or mild dementia associated with amyloid pathology.
The company operates without internal commercial manufacturing, storage, or distribution facilities, relying instead on specialized contract manufacturers to supply drug substances, drug products, and raw materials for clinical programs. The provided text discusses clinical operations within the United States but does not state the company's headquarters location or full operational scale.
Summary of the business section of Acumen Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Acumen Pharmaceuticals, Inc.
- Headquarters
- Newton, MA
- Address
- 1210-1220 Washington Street, Suite 210 02465
- Phone
- (617) 344-4190
- Website
- acumenpharm.com
- Employees
- 61, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- ABOS
- Exchange
- Nasdaq
- IPO date
- Jul 2, 2021
- Shares outstanding
- 72M, Aug 7, 2026
- Public float
- $45.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1576885
- CUSIP
- 00509G209
- ISIN
- US00509G2093
- EIN
- 36-4108129
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Joseph OConnell | Chief Executive Officer, Director | 881,275 |
| Derek M. Meisner | Chief Legal Officer & Corp Sec | 173,999 |
| Eric Siemers | Chief Medical Officer | 255,371 |
| Russell Barton | Chief Operating Officer | 205,092 |
| Matt Zuga | CFO & Chief Business Officer | 304,924 |
| James J. Doherty | President and CDO | 220,900 |
| Amy Schacterle | Chief Regulatory Officer | 92,303 |
| Derrell Porter | Director | 48,540 |
| Nathan B. Fountain | Director | 48,150 |
| Kimberlee C. Drapkin | Director | 48,300 |
| John A. Stalfort III | Director | 352,219 |
| Rajeev M. Shah | Director | 19,103,785 |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | 13,043,179 |
| RA Capital Nexus Fund II, L.P. | Director | 48,300 |
| Laura Stoppel | Director | 48,300 |
| George Golumbeski | Director | 35,500 |
| Jeffrey L. Ives | Director | 48,300 |
| Capital Healthcare Fund LP RA | Director | 12,800 |
Employees
Headcount reported in annual reports
“As of March 25, 2026, we had 61 employees, 60 of which were full time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 2, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 28, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |